Co-Authors
This is a "connection" page, showing publications co-authored by MIEN-CHIE HUNG and LEI NIE.
Connection Strength
4.849
-
Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells. Am J Cancer Res. 2023; 13(4):1209-1239.
Score: 0.919
-
Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2020 Jan 29; 11(1):673.
Score: 0.736
-
CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114.
Score: 0.724
-
Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res. 2012; 4(2):127-50.
Score: 0.428
-
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer. 2022 10; 3(10):1211-1227.
Score: 0.222
-
Author Correction: PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020 Nov; 22(11):1396.
Score: 0.194
-
PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020 10; 22(10):1264-1275.
Score: 0.192
-
Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERa expression in high-grade serous ovarian carcinoma. Am J Cancer Res. 2020; 10(4):1194-1206.
Score: 0.186
-
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res. 2020; 10(2):648-661.
Score: 0.184
-
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019 07 15; 129(8):3324-3338.
Score: 0.177
-
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. Am J Cancer Res. 2019; 9(3):608-618.
Score: 0.173
-
Targeting PKCd as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell. 2018 12 10; 34(6):954-969.e4.
Score: 0.170
-
GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016 Aug 30; 7(35):57131-57144.
Score: 0.145
-
Selective expression of constitutively active pro-apoptotic protein BikDD gene in primary mammary tumors inhibits tumor growth and reduces tumor initiating cells. Am J Cancer Res. 2015; 5(12):3624-34.
Score: 0.137
-
Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res. 2015; 7(6):1009-20.
Score: 0.133
-
Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. Am J Transl Res. 2014; 6(6):649-63.
Score: 0.128